Thursday, June 25, 2026
🇺🇸 FDA

QA/QC Tools · Cleaning Validation · MACO · PDE/ADE

Cleaning Validation Limit Calculator

Free MACO and ADE calculator for pharmaceutical cleaning validation in multi-product GMP facilities. Estimate PDE-based carryover, ppm, surface residue, and swab limits—no MDCalc or Pharmaguddu equivalent for this QA workflow.

Quick Answer

Pharmaceutical cleaning validation limits define how much previous-product residue may carry over into the next batch on shared equipment. Maximum allowable carryover (MACO) is typically derived from a health-based exposure limit (PDE or ADE), then converted to ppm in the next product, total surface residue, µg/cm², and swab acceptance amounts using batch size, maximum daily dose, equipment surface area, and validated swab recovery. Limits require qualified toxicology review, worst-case product selection, and approved GMP SOPs—not calculator output alone.

PDE/ADE based MACO approach

MACO = HBEL × next batch size / max daily dose of next product

HBEL = approved PDE or ADE. This page converts the entered micrograms/day value to milligrams/day before calculating MACO. Surface limit = MACO / shared equipment surface. Swab limit = surface limit × swab area, interpreted with validated recovery per site SOP.

Cleaning Limit Calculator

Enter approved PDE/ADE and equipment parameters to estimate MACO, surface, and swab limits.

Health-based exposure

Micrograms per day, from approved toxicology assessment.

For labeling only. The arithmetic is the same.

Next product & equipment

Kilograms of the next product batch.

Milligrams per day of next product administered.

Square centimeters in the shared equipment train.

Square centimeters sampled by one swab.

Percent recovery from method validation.

Calculated Limits

MACO
-
mg per next batch
Product limit
-
mg/kg (ppm)
Surface limit
-
micrograms/cm2
Swab result limit
-
micrograms recovered/swab
Cleaning validation calculation detail
Exposure basis used-
HBEL converted to mg/day-
Total allowable residue on equipment-
True residue per swab area before recovery-
Recovery-corrected interpretationEnter data to calculate.

How to Use the Cleaning Limit Calculator

1
Confirm the worst-case previous product and next product pair is defined in the approved cleaning validation strategy for the shared equipment train.
2
Enter the PDE or ADE from the qualified toxicology report—not derived from label dose alone unless that approach is explicitly approved in your SOP.
3
Enter next product batch size, maximum daily dose, total contact surface area of the shared train, swab area, and validated swab recovery percentage.
4
Review MACO, ppm, surface limit (µg/cm²), and swab acceptance. Verify the analytical method LOQ is below the calculated limit.
5
Document limits in the cleaning validation protocol and link ongoing monitoring to change control, periodic review, and audit readiness evidence.

Worked Example

Tablet granulation shared equipment train

Inputs: PDE 100 µg/day, next batch 250 kg, max daily dose 2,000 mg, shared surface 125,000 cm², swab area 100 cm², recovery 70%.

HBEL: 100 µg/day = 0.1 mg/day.

MACO: (0.1 mg/day × 250,000,000 mg batch) / 2,000 mg/day = 12,500 mg per next batch.

Product limit: 12,500 mg / 250 kg = 50 ppm (50 mg/kg).

Surface limit: 12,500,000 µg / 125,000 cm² = 100 µg/cm².

Swab (70% recovery): true residue 10,000 µg/swab → recovered acceptance ≈ 7,000 µg/swab per this calculator’s convention.

Interpretation: HBEL yields 50 ppm, but the legacy 10 ppm criterion is stricter—apply the lowest applicable limit unless protocol defines HBEL as the sole governing criterion with toxicology sign-off.

Cleaning Limit Approach Reference

Approach Basis Typical application QA note
PDE / ADE (HBEL) Toxicology Multi-product shared facilities Primary approach under EMA HBEL and ISPE Risk-MaPP
10 ppm Quality criterion Legacy programs; secondary check Not sufficient alone for potent or sensitizing actives
0.001 dose Therapeutic margin Low-risk products without HBEL Starting point only; toxicologist review for shared trains
Visual cleanliness Qualitative inspection Periodic monitoring; large surfaces Cannot replace analytical limits for potent compounds

Pharma / GMP Context for QA Professionals

Cleaning validation limits are a core cross-contamination control in multi-product pharmaceutical facilities. Under EU GMP Chapter 3 and Annex 15—and aligned PIC/S expectations—manufacturers must demonstrate that equipment cleaning reduces previous-product residues to scientifically justified levels before the next product is manufactured. MACO derived from PDE or ADE is the arithmetic bridge between toxicology and shop-floor swab/rinse acceptance criteria.

Health-based exposure limits should be established per EMA shared-facility HBEL guidance and ISPE Risk-MaPP, with ICH Q9(R1) quality risk management governing worst-case product selection, equipment grouping, and periodic review. Link limit calculations to process validation evidence using our Process Capability Cpk Calculator for variable CQAs, and to inspection preparedness via the GMP Checklist Generator and Audit Readiness Checklist.

API manufacturers follow APIC cleaning validation guidance; finished-dose sites reference FDA’s cleaning validation inspection guide and 21 CFR 211.67 equipment cleaning requirements. Detergent residues, bioburden, endotoxin, hold times, and campaign length may impose limits stricter than MACO—document the controlling criterion in the validation report.

Toxicology and SOP Caveats

  • PDE or ADE should come from a qualified toxicological assessment. Do not derive it casually from public dose information.
  • Equipment train surface area, next product batch size, dose, route, and worst-case product selection must be defined by an approved cleaning validation strategy.
  • Swab recovery can be handled by lowering the reportable limit or by correcting measured results. Follow the approved SOP and validation report.
  • Analytical method LOQ must be suitable for the calculated residue limit. If the method cannot quantify the limit, the cleaning strategy needs review.
  • Visual cleanliness, detergent residues, bioburden, endotoxin, and campaign length may impose additional limits beyond MACO.

Sources and Regulatory Context

Frequently Asked Questions

MACO means maximum allowable carryover—the largest mass of residue from a previous product permitted to transfer into the next product batch on shared equipment. It is usually calculated from an approved health-based exposure limit (PDE or ADE) and the next product’s batch size and maximum daily dose, then allocated to equipment surfaces and swab sampling locations. MACO is a documented acceptance criterion within a validated cleaning program, not a standalone regulatory number.
ADE (acceptable daily exposure) is a health-based limit for residual carryover, often derived by qualified toxicologists from pharmacological and toxicological data. PDE (permitted daily exposure) is the EMA term for the same risk-based concept in shared-facility guidance. ISPE Risk-MaPP and EMA HBEL documents treat PDE and ADE as effectively synonymous for cleaning validation when established by the same toxicological principles. Site SOPs must define which term and derivation method apply.
The 10 ppm rule is a legacy quality-based carryover criterion: residue of the previous product in the next batch should not exceed 10 parts per million (10 mg/kg). It was widely used before health-based exposure limits became the primary framework for multi-product facilities. It may still appear in older protocols or as a secondary check, but it is not scientifically justified for all actives—especially potent, toxic, or sensitizing compounds—and should not replace PDE/ADE-based limits where HBELs are required.
The 0.001 dose criterion sets carryover at 0.1% (1/1000) of the minimum therapeutic dose of the previous product in the maximum daily dose of the next product. It provides a therapeutic-margin approach when full toxicological HBEL data are unavailable for low-risk products. ISPE Risk-MaPP cites it as a starting point, but potent drugs, narrow therapeutic index products, and shared facilities under EMA HBEL expectations typically require formal PDE/ADE assessment instead of dose-fraction alone.
For shared equipment, MACO is first calculated from the HBEL and next-product parameters, then the total allowable residue on the equipment train is allocated across the validated contact surface area to yield a limit in µg/cm². Swab limits apply that surface concentration to the swabbed area and may adjust for validated recovery. Worst-case product pairs, hardest-to-clean locations, and the full equipment train—not isolated vessels—must be defined in the cleaning validation protocol.
Therapeutic class grouping assigns a single cleaning limit to a family of structurally or pharmacologically similar products when scientific justification shows equivalent toxicity and cleanability. It reduces redundant validation but requires documented rationale, bracketing/worst-case selection, and regulator-agreed criteria. It is not appropriate when products differ in potency, sensitization, mutagenicity (ICH M7), or HBEL. Class-based limits must still meet the strictest member’s health-based requirement.
Swab sampling is preferred for small internal surfaces, valves, gaskets, and locations where rinse recovery is poor or not representative. Rinse sampling suits large vessels and piping when rinse volume, agitation, and recovery studies demonstrate representative residue recovery. Many protocols use both: rinse for overall equipment verification and swabs for worst-case hard-to-clean sites. The acceptance limit calculation must match the validated sampling method and recovery factor.
Visual inspection confirms absence of visible residue at defined lighting and viewing conditions and is required under cGMP as a minimum check. For many non-potent products, visual cleanliness at a validated threshold (often ~100 µg/cm² for stainless steel, product-specific) may support periodic monitoring. Visual criteria alone cannot validate cleaning of potent, highly active, or sensitizing compounds—analytical limits based on HBEL or justified quality criteria are required.
Cleaning validation follows a lifecycle aligned with Annex 15 and FDA process validation principles: development and risk assessment, protocol-defined qualification runs on worst-case products and soiled conditions, analytical method validation with recovery studies, ongoing monitoring, and change control when products, equipment, or procedures change. Revalidation triggers include new products on shared trains, procedure changes, failed results, and periodic review. MACO limits are documented inputs to this lifecycle—not one-time calculations.
FDA’s Guide to Inspections of Validation of Cleaning Processes (7/93) establishes the expectation that cleaning procedures be validated, with documented limits, sampling, analytical methods, and recovery. FDA cGMP Q&A on equipment (21 CFR 211.67) reinforces validated cleaning and acceptable residue levels. FDA expects scientifically justified limits, worst-case product selection, and evidence that residues are reduced to acceptable levels—health-based limits are consistent with current inspection focus on cross-contamination in multi-product facilities.
A qualified toxicologist should derive or review PDE/ADE values for active substances and degradants used in shared-facility MACO calculations, especially for potent compounds, mutagenic impurities (ICH M7), reproductive toxins, sensitizers, and new products without established HBELs. Toxicology input is expected under EMA HBEL guidance and ISPE Risk-MaPP. QA may perform arithmetic from approved HBEL reports, but toxicologists own hazard identification, dose-response assessment, and document sign-off.
The core MACO formula is: MACO (mg) = HBEL (mg/day) × next batch size (mg) ÷ maximum daily dose of next product (mg/day). Product limit (ppm) = MACO (mg) ÷ batch size (kg). Surface limit (µg/cm²) = MACO (µg) ÷ shared equipment contact surface area (cm²). Swab acceptance = surface limit × swab area, adjusted per validated recovery per site SOP. Always use values from the approved toxicology report and cleaning validation protocol.

Related Tools

Cpk Process Capability Cpk GMP GMP Checklist Generator Audit Audit Readiness Checklist RPN RPN Calculator ISO Cleanroom Classification

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.